DUBLIN--(BUSINESS WIRE)--The "Myasthenia Gravis (MG) - Epidemiology Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
Myasthenia Gravis (MG) - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Myasthenia Gravis (MG) epidemiology division provide the insights about historical and current patient pool and forecasted trend for 7 major countries. The epidemiology data for Myasthenia Gravis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology {total prevalent cases, gender-specific cases, severity-specific prevalent cases [Class I, Class II (Class IIa, IIb), Class III (Class IIIa, IIIb), Class IV & Class V], auto-antibodies specific prevalent cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] and diagnosed cases} scenario of Myasthenia Gravis (MG) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
Key Topics Covered:
1. Key Insights
2. Myasthenia Gravis Market Overview at a Glance
3. Market Share (%) Distribution of MG in 2017
4. Market Share (%) Distribution of MG in 2027
5. Disease Overview: Myasthenia Gravis
6. Epidemiology and Patient Population
7. Market Drivers
8. Market Barriers
9. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/xf7qw9/global_myasthenia?w=4
